Meyeon Park1, Ameya Kulkarni2, Alexis Beatty3, Peter Ganz4, Mathilda Regan5, Eric Vittinghoff6, Mary Whooley7. 1. Division of Nephrology, University of California, San Francisco (UCSF), San Francisco, CA, USA. Electronic address: meyeon.park@ucsf.edu. 2. Kaiser Permanente, McLean, VA, USA. 3. Division of Cardiology, VA Puget Sound Health Care System, University of Washington, USA. 4. Division of Cardiology, VA Puget Sound Health Care System, University of Washington, USA; Division of Cardiology, University of California San Francisco and San Francisco General Hospital, USA. 5. Department of Medicine, San Francisco VA Hospital, San Francisco, CA, USA. 6. Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA. 7. Department of Medicine, San Francisco VA Hospital, San Francisco, CA, USA; Department of Medicine, UCSF, San Francisco, CA, USA; Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA, USA.
Abstract
BACKGROUND AND AIMS: Endothelial cell-selective adhesion molecule (ESAM) is selectively expressed on vascular endothelium and is postulated to play a role in atherogenesis. We investigated the association of serum soluble ESAM (sESAM) levels with subsequent cardiovascular outcomes in patients with stable ischemic heart disease. METHODS: We measured sESAM levels in 981 patients with stable coronary disease enrolled between September 2000 and December 2002 in a prospective cohort study. Poisson regression models were used to define the relationship between baseline sESAM levels and cardiovascular outcomes, including myocardial infarction, heart failure hospitalization, and mortality. RESULTS: There were 293 occurrences of the composite endpoint over a median follow-up of 8.9 years. After adjusting for demographic and clinical risk factors, participants in the highest sESAM quartile (compared to the lower three sESAM quartiles) had a higher rate of the composite endpoint (incident rate ratio (IRR) 1.52 (95% CI 1.16-1.99) as well as of its individual components: myocardial infarction (IRR 1.64 (1.06-2.55)), heart failure hospitalizations (IRR 1.96 (1.32-2.81)), and death (IRR 1.5 (1.2-1.89)). These associations were no longer significant after adjustment for estimated glomerular filtration rate. CONCLUSIONS: sESAM levels associate with myocardial infarction, heart failure, and death after adjustment for demographic and clinical risk factors, but not after adjustment for kidney function. sESAM may be involved in the pathogenesis of concurrent kidney and cardiovascular disease.
BACKGROUND AND AIMS: Endothelial cell-selective adhesion molecule (ESAM) is selectively expressed on vascular endothelium and is postulated to play a role in atherogenesis. We investigated the association of serum soluble ESAM (sESAM) levels with subsequent cardiovascular outcomes in patients with stable ischemic heart disease. METHODS: We measured sESAM levels in 981 patients with stable coronary disease enrolled between September 2000 and December 2002 in a prospective cohort study. Poisson regression models were used to define the relationship between baseline sESAM levels and cardiovascular outcomes, including myocardial infarction, heart failure hospitalization, and mortality. RESULTS: There were 293 occurrences of the composite endpoint over a median follow-up of 8.9 years. After adjusting for demographic and clinical risk factors, participants in the highest sESAM quartile (compared to the lower three sESAM quartiles) had a higher rate of the composite endpoint (incident rate ratio (IRR) 1.52 (95% CI 1.16-1.99) as well as of its individual components: myocardial infarction (IRR 1.64 (1.06-2.55)), heart failure hospitalizations (IRR 1.96 (1.32-2.81)), and death (IRR 1.5 (1.2-1.89)). These associations were no longer significant after adjustment for estimated glomerular filtration rate. CONCLUSIONS:sESAM levels associate with myocardial infarction, heart failure, and death after adjustment for demographic and clinical risk factors, but not after adjustment for kidney function. sESAM may be involved in the pathogenesis of concurrent kidney and cardiovascular disease.
Authors: Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong Journal: Circulation Date: 2002-10-01 Impact factor: 29.690
Authors: Russell V Luepker; Fred S Apple; Robert H Christenson; Richard S Crow; Stephen P Fortmann; David Goff; Robert J Goldberg; Mary M Hand; Allan S Jaffe; Desmond G Julian; Daniel Levy; Teri Manolio; Shanthi Mendis; George Mensah; Andrzej Pajak; Ronald J Prineas; K Srinath Reddy; Veronique L Roger; Wayne D Rosamond; Eyal Shahar; A Richey Sharrett; Paul Sorlie; Hugh Tunstall-Pedoe Journal: Circulation Date: 2003-11-10 Impact factor: 29.690
Authors: N B Schiller; P M Shah; M Crawford; A DeMaria; R Devereux; H Feigenbaum; H Gutgesell; N Reichek; D Sahn; I Schnittger Journal: J Am Soc Echocardiogr Date: 1989 Sep-Oct Impact factor: 5.251
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Mary S Beattie; Michael G Shlipak; Haiying Liu; Warren S Browner; Nelson B Schiller; Mary A Whooley Journal: Circulation Date: 2003-01-21 Impact factor: 29.690
Authors: Frank Wegmann; Björn Petri; Alexander Georg Khandoga; Christian Moser; Andrej Khandoga; Stefan Volkery; Hang Li; Ines Nasdala; Oliver Brandau; Reinhard Fässler; Stefan Butz; Fritz Krombach; Dietmar Vestweber Journal: J Exp Med Date: 2006-07-03 Impact factor: 14.307
Authors: Lotte Slenders; Lennart P L Landsmeer; Kai Cui; Marie A C Depuydt; Maarten Verwer; Joost Mekke; Nathalie Timmerman; Noortje A M van den Dungen; Johan Kuiper; Menno P J de Winther; Koen H M Prange; Wei Feng Ma; Clint L Miller; Redouane Aherrahrou; Mete Civelek; Gert J de Borst; Dominique P V de Kleijn; Folkert W Asselbergs; Hester M den Ruijter; Arjan Boltjes; Gerard Pasterkamp; Sander W van der Laan; Michal Mokry Journal: Eur Heart J Open Date: 2021-12-21